Summary
Of the 3 most widely used calcium antagonists — nifedipine, verapamil and diltiazem — nifedipine is the most potent arterial vasodilator. Increases in cardiac output and coronary blood flow following nifedipine administration result in part from the afterload reduction. Reflex adrenergic stimulation produces an increase in heart rate and masks a direct inhibitory effect on myocardial contractility. The negative inotropic action of nifedipine is observed during intracoronary administration or may be made apparent by concurrent β-blocker therapy.
While verapamil is also a potent vasodilator, negative inotropic and dromotropic properties are more apparent in therapeutically used dosages. Reflex sympathetic activation is also triggered by verapamil, with an offsetting of the negative inotropic effects such that little change in cardiac output results. A decrease in myocardial oxygen consumption, with or without a decrease in coronary sinus blood flow, has regularly been observed following verapamil administration. Reduced oxygen demand appears to he a major mechanism of its antianginal effect. The heart rate × systolic pressure product is decreased both by the fall in arterial pressure and, particularly after oral administration, by a decrease in heart rate.
Diltiazem produces similar haemodynamic and electrophysiological effects to those of verapamil but has less potency in inducing arterial dilatation and more of a tendency to slow the heart rate. Diltiazem does not appear to cause significant increases in coronary blood flow or bring about improvement in ejectional and isovolumic indices of myocardial contraction — evidence of its intrinsic negative inotropic effect.
Similar content being viewed by others
References
Amende I, Simon R, Hood WP, Hetzer R, Lichtlen PR. Intracoronary nifedipine in human beings: magnitude and time course of changes in left ventricular contraction/relaxation and coronary sinus blood flow. Journal of the American College of Cardiology 2: 1141–1145, 1983
Amende I, Simon R, Lichtlen PR. Early effects of nifedipine on left ventricular diastolic function in man. Abstract. Circulation 62(Suppl. 3): 259, 1980
Anastassiades CJ. Nifedipine and beta-blocking drugs. British Medical Journal 281: 1251–1252, 1980
Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, et al. Nifedipine therapy for coronary artery spasm. New England Journal of Medicine 302: 1269–1273, 1980
Aoki K, Sato Y, Kawaguchi Y, Yamamoto M. Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension. European Journal of Clinical Pharmacology 23: 197–201, 1982
Atterhog JH, Ekelund LG. Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men. European Journal of Clinical Pharmacology 8: 317–322, 1975
Bagger JP, Nielsen TT. Influence of nifedipine on coronary haemodynamics and myocardial metabolism in coronary artery disease. European Heart Journal 6: 75–84, 1985
Bass O, Friedemann M. Ein beitrag zum anti-arrhytmischen Wirkungs mechanismus von Verapamil. Schweizerische Medizinische Wochenschrift 101: 792–799, 1971
Belloci F, Ansalone G, Santarelli P, Loperfido F, Scabbia et al. Oral nifedipine in the long-term management of severe chronic heart failure. Journal of Cardiovascular Pharmacology 4: 847–855, 1982
Bertrand ME, Dupuis BA, Lablanche JM, Tilmant PJ, Thieuleux FA. Coronary hemodynamics following intravenous or intracoronary injection of diltiazem in man. Journal of Cardiovascular Pharmacology 4: 695–699, 1982
Bertrand ME, Lablanche JM, Tilmant PY. Treatment of spasm of the coronary artery with nifedipine. European Heart Journal 1(Suppl. B): 65–69, 1980
Bertrand ME, Lablanche JM, Tilmant PY. Treatment of Prinzmetal’s variant angina: role of medical treatment with nifedipine and surgical coronary revascularization combined with plexectomy. American Journal of Cardiology 47: 174–178, 1981
Biamino G, Oeff M, Prokein E, Schroder R. Verhalten von Hämodynamik und Koronardurchblutting nach intravenoser Gabe von Diltiazem bei Koronarer Herzerkrankung. In Bender & Greef (Eds) Calciumantagonisten zur Behandlung der Angina Pectoris, Hypertonie und Arrhythmie, pp. 94–103, Excerpta Medica, Amsterdam-Oxford-Princeton, 1982
Bonow RO, Leon MB, Rosing DR, Kent KM, Lipson LC, et al. Effects of verapamil and propranolol on left ventricular systolic function and diastolic filling in patients with coronary artery disease: radionuclide angiographic studies at rest and during exercise. Circulation 65: 1337–1350, 1982
Bonzel T, Wollschlager H, Tamowska R, Lollgen H, Zeiher A, et al. Dilatation of epicardial and intramyocardial coronary arteries and collaterals by intravenous diltiazem in patients with coronary artery disease, in press, 1986
Bos RJ, Serruys PW, Brower RW, ten Katen HJ, Vanhaleweyk G, Hugenholtz PG. Effect of long-term oral nifedipine therapy on left ventricular regional wall function at rest and during supine bicycle exercise. European Heart Journal 6: 349–357, 1985
Bourassa MG, Cote PC, Theroux P, Tubau JF, Genain C, et al. Hemodynamics and coronary flow following diltiazem administration in anesthetized dogs and humans. Chest 78 (Suppl.): 224–230, 1980
Brittinger WD, Schwarzbeck A, Wittemeier KW, Twittenhoff WD, Stegaru B. Klinisch experimentelle Untersuchungen uber die blutdrucksenkende Wirkung von Verapamil. Deutsche Medizinische Wochenschrift 1871–1877, 1980
Brooks N, Cattell M, Pidgeon J, Balcon R. Unpredictable response to nifedipine in severe cardiac failure. British Medical Journal 281: 1324, 1980
Browne RK, Dimmit DC, Miller LD, Korol B. Relationship between plasma diltiazem and cardiovascular responses in conscious dogs. Journal of Cardiovascular Pharmacology 5: 483–490, 1983
Canlelli I, Pavesi PC, Naccarella F, Bracchetti D. Acute haemodynamic effects combined therapy with digoxin and nifedipine in patients with chronic heart failure. American Heart Journal 106: 308–315, 1983
Chew CYC, Brown G, Singh BN, Wong MM, Pierce C, et al. Effects of verapamil on coronary hemodynamic function and vasomobility relative to its mechanism of antianginal action. American Journal of Cardiology 51: 699–705, 1983
Chew CYC, Hecht HS, Collett JT, McAllister RG, Singh BN. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. American Journal of Cardiology 47: 917–922, 1981
Daly K, Bergman G, Rothman M, Atkinson L, Jackson G, et al. Beneficial effect of adding nifedipine to beta-adrenergic blocking therapy in angina pectoris. European Heart Journal 3: 42–46, 1982
Dash H, Copenhaver GL, Ensminger S. Improvement in regional wall motion and left ventricular relaxation after administration of diltiazem in patients with coronary artery disease. Circulation 72: 353–363, 1985
De Jong JW, Harmsen E, de Tombe PP, Keijzer E. Nifedipine reduces adenine nucleotide breakdown in ischaemic rat heart. European Journal of Pharmacology 81: 89–96, 1982
De Servi S, Mussini A, Specchia G, Bramucci E, Gavazzi A, et al. Effects of nifedipine on coronary blood flow and coronary resistance during cold pressor test and isometric exercise in patients with coronary artery disease. European Heart Journal 1(Suppl. B): 43–47, 1980
Deanfield J, Wright C, Fox K. Treatment of angina pectoris with nifedipine: importance of dose titration. British Medical Journal 286: 1467–1470, 1983
Eichelbaum M, Somogyi A, von Unruh GE, Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D, L-verapamil using stable isotope-labelled verapamil. European Journal of Clinical Pharmacology 19: 133–137, 1981
Elkayam V, Weber L, McKay CR, Rahimtoola SH. Differences in haemodynamic response to vasodilatation due to calcium channel antagonism with nifedipine and direct-acting agonism with hydrallazine in chronic refractory congestive heart failure. American Journal of Cardiology 54: 126–131, 1984
Emanuelsson H, Holmberg S. Mechanisms of angina relief after nifedipine: a hemodynamic and myocardial metabolic study. Circulation 68: 124–130, 1983
Engel HJ, Wolf R, Hundeshagen H, Lichtlen PR. Different effects of nitroglycerine and nifedipine on regional myocardial blood flow during pacing induced angina pectoris. European Heart Journal 1(Suppl. B): 53–58, 1980
Esper RJ, Machado RA, Nordaby RA, Bidoggia HJ. Comparative investigations with nifedipine in healthy subjects and patients with coronary artery disease (phonomechano-cardiograms). In Jatene & Lichtlen (Eds) Proceedings of the 3rd International Adalat Symposium, pp. 147–168, Excerpta Medica, Amsterdam-Oxford, 1976
Ferlinz J, Citron PD. Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure. American Journal of Cardiology 51: 1339–1345, 1983
Ferlinz J, Easthope JL, Aronow WS. Effects of verapamil on myocardial performance in coronary disease. Circulation 59: 313–319. 1979
Ferlinz J, Stavens CS. Effects of intracoronary and intravenous verapamil on coronary blood flow and caliber of epicardial vessels in coronary disease. Abstract. Circulation 68(Suppl. 3): III–18, 1983
Ferlinz I, Turbow ME. Antianginal and myocardial metabolic properties of verapamil in coronary artery disease. American Journal of Cardiology 46: 1019–1026, 1980
Fernandez F, Belfante M, Juillard A, Batalla N, Baclet M, et al. Effects du diltiazem sur les circulations cardiaque et coronaire, au repos et au cours de la stimulation electrique auriculair rapide. Archives des Maladies du Coeur 76: 61–70, 1983
Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. Journal of Clinical Pharmacology 25: 161–170, 1983
Gillmer DJ, Kark P. Pulmonary oedema precipitated by nifedipine. British Medical Journal 280: 1420–1421, 1980
Goldberg S, Reichek N, Wilson J, Hirshfeld Jr JW, Muller J, et al. Nifedipine in the treatment of Prinzmetal’s angina. American Journal of Cardiology 44: 804–810, 1979
Goldhaber SZ, White HD, Holman BL, Nesto RW, Mudge GH, et al. Prevention by nifedipine of cold pressor-induced decrease in left ventricular ejection fraction. Journal of the American College of Cardiology 1: 1512–1517, 1983
Guazzi MD, Cipolla C, Bella PD, Fabbiocchi F, Montorsi P, et al. Disparate unloading efficacy of the calcium channel blockers, verapamil and nifedipine, on the failing hypertensive left ventricle. American Heart Journal 108: 116–123, 1984
Gunther S, Green L, Muller JE, Mudge GH, Grossman W. Prevention by nifedipine of abnormal coronary vasoconstriction in patients with coronary artery disease. Circulation 63: 849–855, 1981
Hamann SR, Kaltenborn KE, McAllister RG. Pharmacodynamic comparison of verapamil and nifedipine in anesthetized dogs. Journal of Clinical Pharmacology, in press, 1986
Hamann SR, McAllister RG. Plasma concentrations and hemodynamic effects of nifedipine: a study in anesthetized dogs. Journal of Clinical Pharmacology 5: 920–927, 1983
Hanrath P, Kremer P, Bleifeld W. Influence of nifedipine on left ventricular dysfunction at rest and during exercise. European Heart Journal 3: 325–330, 1982
Hecht HS, Chew CYC, Burnam MH, Hopkins J, Schnugg S, et al. Verapamil in chronic stable angina: amelioration of pacing-induced abnormalities of left ventricular ejection fraction, regional wall motion, lactate metabolism and hemodynamics. American Journal of Cardiology 48: 536–544, 1981
Heeger H, Kahn P, Aldor E. Myocardial circulation under Adalat in different phases of coronary disease. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 204–209, Springer-Verlag, Berlin-Heidelberg-New York, 1975
Hollmann W, Rost R, Liesen H, Emirkanian O. The cardiopulmonary loading capacity in healthy persons and patients with coronary artery disease after application of Adalat. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 243–247, Springer Verlag, Berlin-Heidelberg-New York, 1975
Hopf R, Kaltenbach M, Kober G. Verapamil in the treatment of hypertrophic obstructive cardiomyopathy. In Zanchetti & Krikler (Eds) Calcium antagonism in cardiovascular therapy, pp. 353–362, Excerpta Medica, Amsterdam-Oxford, 1980
Hossack KF, Brown BG, Stewart DK, Dodge HT. Diltiazem-induced blockade of sympathetically mediated constriction of normal and diseased coronary arteries: lack of epicardial dilatory effect in humans. Circulation 70: 465–471, 1984
Hossack KF, Bruce RA. Improved exercise performance in persons with stable angina pectoris receiving diltiazem. American Journal of Cardiology 47: 95–101, 1981
Hugenholtz PG, Michels HR, Serruys PW, Brower RW. Nifedipine in the treatment of unstable angina, coronary artery spasm and myocardial ischemia. American Journal of Cardiology 47: 163–173, 1981
Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, et al. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation 68: 560–567, 1983
Johnston DL, Gebhardt VA, Donald A, Kostuk WJ. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, cross-over study with radionuclide ventriculography. Circulation 68: 1280–1289, 1983
Josephson MA, Hecht HS, Hopkins JM, Singh BN. Oral verapamil vs propranolol in coronary artery disease: evaluation of left ventricular function by exercise radionuclide ventriculography. Abstract. American Journal of Cardiology 47: 463, 1981
Joshi PI, Dalal JJ, Ruttley MSJ, Sheridan DJ, Henderson AH. Nifedipine and left ventricular function in beta-blocked patients. British Heart Journal 45: 457–459, 1981
Joyal M, Cremer KF, Feldman L, Pieper JA, Pepine CJ. Is coronary vasodilation due to diltiazem responsible for relief of stress-induced angina? Circulation 68(Suppl. 3): III–18, 1983
Joyal M, Cremer KF, Peper JA, Feldman RL, Pepine CJ. Systemic, left ventricular and coronary hemodynamic effects of intravenous diltiazem in coronary artery disease. American Journal of Cardiology 56: 413–417, 1985
Kaltenbach M, Schulz W, Kober G. Effects of nifedipine after intravenous and intracoronary administration. American Journal of Cardiology 44: 832–836, 1979
Kenny J, Daly K, Bergman G, Kerkez S, Jackson G, et al. The haemodynamic and metabolic effects of diltiazem, a new calcium antagonist, in patients with coronary artery disease. Irish Journal of Medical Science 151: 29–34, 1982
Kenny J, Daly K, Bergman G, Kerkez S, Jewitt DE. Beneficial effects of diltiazem combined with beta blockade in angina pectoris. European Heart Journal 6: 418–423, 1985
Kieval J, Kirsten EB, Kessler KM, Mallon SM, Myerburg RJ. The effects of intravenous verapamil on hemodynamic status of patients with coronary artery disease receiving propranolol. Circulation 65: 653–659, 1982
Kinney EL, Moskowitz RM, Zelis R. The pharmacokinetics and pharmacology of oral diltiazem in normal volunteers. Journal of Clinical Pharmacology 21: 337–342, 1981
Kinoshita M, Motomura M, Kusakawa R, Kawakita S. Comparison of hemodynamic effects between beta-blocking agents and a new anti-anginal agent, diltiazem hydrochloride. Japanese Circulation Journal 43: 587–598, 1979
Klein HO, Ninio R, Oren V, Lang R, Sareli P, et al. The acute hemodynamic effects of intravenous verapamil in coronary artery disease. Assessment by equilibrium-gated radionuclide ventriculography. Circulation 67: 101–110, 1983
Klugman S, Salvi A, Camerini F. Haemodynamic effects of nifedipine in heart failure. British Heart Journal 43: 440–446, 1980
Kober G, Becker HJ, Kaltenbach M. Left ventricular hemodynamics in patients at rest before and after nifedipine. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 164–167, Springer Verlag, Berlin-Heidelberg-New York, 1975
Kober G, Schulz W, Scherer D, Kaltenbach M. Linksventriculare Funktion und Hemodynamik bei intrakoronarer und intravenoser Gabe von Diltiazem. In Bender and Greeff (Eds) Calciumantagonisten zur Behandlung der Angina pectoris, Hypertonie und Arrhythmie, pp. 87–93, Excerpta Medica, Amsterdam-Oxford-Princeton, 1982
Koch G. Beta-receptor and calcium blockade in ischemic heart disease: effects on systemic and pulmonary hemodynamics and on plasma catecholamines at rest and during exercise. In Puech & Krebs (Eds) Fourth International Adalat Symposium, pp. 131–142, Excerpta Medica, Amsterdam/Oxford/Princeton, 1980
Kohler JA. The effect of Adalat on coronary circulation after sublingual administration. In Lochner et al. (Eds) Proceedings of the 2nd Adalat Symposium, pp. 234–235, Springer Verlag, Berlin-Heidelberg-New York, 1975
Koiwaya J, Takeshita A, Nakamura M. Hemodynamic effects of intravenous diltiazem in patients with recent myocardial infarction. Clinical Therapeutics 4: 381–389, 1982
Kurita A. Effect of Adalat on left ventricular hemodynamics in angina pectoris (comparative study with propranolol). In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 225–231, Springer Verlag, Berlin-Heidelberg-New York, 1975
Kurnik PB, Tiefenbrunn AJ, Ludbrook PA. The dependence of the cardiac effects of nifedipine on the responses of the peripheral vascular system. Circulation 69: 963–972, 1984
Kusakawa R, Kinoshita M, Shimono Y, Tomonaga G, Hoshino T. Hemodynamic effects of a new anti-anginal drug, diltiazem hydrochloride. Arzneimittel-Forschung 27: 878–883, 1977
Leon MB, Bonow RO, Rosing DR, Bacharach SL, Green MV, et al. Effects of verapamil alone and combined with propranolol on left ventricular function in patients with coronary artery disease. Abstract. Circulation 62(Suppl. 3): 233, 1980
Lichtlen PR. Coronary and left ventricular dynamics under nifedipine in comparison to nitrates, beta-blocking agents and dipyridamole. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 212–224, Springer Verlag, Berlin-Heidelberg-New York, 1975
Low RI, Takeda P, Lee G, Mason DT, Awan NA, et al. Effects of diltiazem induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease. American Heart Journal 101: 713–718, 1981
Ludbrook PA, Tiefenbrunn AJ, Reed FA, Sobel BE. Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function. Circulation 65: 489–498, 1982
Luebs ED, Cohen A, Zaleski EJ, Bing RJ. Report on therapy: effect of nitroglycerine, Intensain, Isoptin and papaverine on coronary blood flow in man. American Journal of Cardiology 17: 535–541, 1966
Lydtin H, Lohmoller G, Lohmoller R, Schmitz H, Walter I. Hemodynamic studies on Adalat in healthy volunteers and in patients. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 112–123, Springer Verlag, Berlin-Heidelberg-New York, 1975
Lydtin H, Schierl W, Lohmoller G. Exercise pulmonary wedge pressure after acute and chronic administration of nifedipine in ischemic heart disease. In Tuech & Krebs (Eds) Proceedings of the 4th International Adalat Symposium, pp. 249–254, Excerpta Medica, Amsterdam-Oxford-Princeton, 1980
Magometschnigg D, Bonelli J, Gassner A, Kaik G, Hitzenberger G. Cardiovascular effects of diltiazem in healthy volunteers at rest, supine and erect, and during physical and mental stress. International Journal of Clinical Pharmacology, Therapy and Toxicology 19: 514–518, 1981
Magorien RD, Leier CV, Kolibash AJ, Barbush TJ, Unverferth DV. Beneficial effects of nifedipine on rest and exercise myocardial energetics in patients with congestive heart failure. Circulation 70: 884–890, 1984
Majid PA, de Jong J. Acute hemodynamic effects of nifedipine in patients with ischemic heart disease. Circulation 65: 1114–1118, 1982
Malacoff RF, Lorell BH, Mudge GH, Holman BL, Idoine J, et al. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 65(Suppl. 1): 32–37, 1982
Manglardi LM, Hariman RJ, McAllister RG, Bhargava V, Surawicz B, et al. Electrophysiologic and hemodynamic effects of verapamil. Correlations with plasma drug concentrations. Circulation 53: 366–372, 1978
Matsumoto S, Takashi I, Toshikatso S, Takahashi M, Su K, et al. Hemodynamic effects of nifedipine in congestive heart failure. American Journal of Cardiology 46: 476–480, 1980
McAllister RG, Hamann R, Blouin RA. Pharmacokinetics of calcium-entry blockers. American Journal of Cardiology 55: 30B–40B, 1985
McAllister RG, Kirsten EB. The pharmacology of verapamil. IV. Pharmacokinetics and drug effects after single intravenous and oral doses in normal subjects. Clinical Pharmacology and Therapeutics 31: 418–426, 1982
Merillon JP, Morgant C, Zygelman M, Beaufils P, Patart O, et al. Comparison des effects hemodynamiques et coronariens de deux drogues vasodilatatrices anti-angineuses: la nifedipine et la trinitrine. Archives des Maladies du Coeur 8: 913–921, 1978
Mostbeck A, Partsch H, Peschl L. Investigations on peripheral blood distribution. In Jatene & Lichtlen (Eds) Proceedings of the 3rd International Adalat Symposium, pp. 91–97, University of Tokyo Press, 1976
Motte G, Chanu B, Sebag C, Benaim P. Nifedipine et bêta-bloqueur: une association potentiellement dangereuse? Nouvelle Presse Medicale 9: 379–380, 1980
Mudge Jr GH, Grossman W, Mills Jr RM, Lesch M, Braunwald E. Reflex increase in coronary vascular resistance in patients with ischemic heart disease. New England Journal of Medicine 295: 1333–1337, 1976
Nelson GIC, Silke B, Ahuja RC, Hussain M, Forsyth D, et al. The effect of left ventricular performance of nifedipine and metoprolol singly and together in exercise-induced angina pectoris. European Heart Journal 5: 67–79, 1984a
Nelson GIC, Silke B, Ahuja RC, Verma SP, Hussain M, et al. Haemodynamic effects of nifedipine during upright exercise in stable angina pectoris and either normal or severely impaired left ventricular function. American Journal of Cardiology 53: 451–455, 1984b
Onno H, Hashimoto K. Ca++ antagonism in various parameters of cardiac function, including coronary dilatation with the use of nifedipine, perhexiline and verapamil. In Winburg & Abiko (Eds) Ischemic myocardium and the antianginal drugs, pp. 77–81, Raven Press, New York, 1979
Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. British Medical Journal 281: 1462, 1980
Packer M, Meller J, Medina N, Yushak M, Smith H, et al. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 65: 660–668, 1982
Parodi O, L’Abbate A, Simonetti I, Severi S, Marzullo P, et al. Verapamil in the treatment of vasospastic angina pectoris. In Zanchetti & Krikler (Eds) Calcium antagonism in cardiovascular therapy, pp. 176–179, Excerpta Medica, Amsterdam-Oxford, 1980
Patton JN, Vlietstra RE, Frye RL. Randomized, placebo-controlled study of the effect of verapamil on exercise hemodynamics in coronary artery disease. American Journal of Cardiology 53: 674–678, 1984
Pedersen OL, Christensen NJ, Ramsch KD. Comparison of acute effects of nifedipine in normotensive and hypertensive man. Journal of Cardiovascular Pharmacology 2: 357–366, 1980
Pepine CJ, Feldman RL, Whittle J, Curry RC, Conti CR. Effect of diltiazem in patients with variant angina: a randomized double-blind trial. American Heart Journal 101: 719–725, 1981
Pfisterer M, Müller-Brand J, Burkart F. Combined acebutolol/ nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced ventricular dysfunction. American Journal of Cardiology 49: 1259–1266, 1982
Piegas LS, Neto FP, Konstadinidis T, de Magalhaes HM, de Souza EMR, et al. Hemodynamic evaluation of a new antianginal drug: nifedipine. In Jatene & Lichtlen (Eds) Proceedings of the 3rd International Adalat Symposium, pp. 76–82, Excerpta Medica, Amsterdam-Oxford, 1976
Polese A, Fiorentini C, Olivari MI, Guazzi MD. Clinical use of a calcium antagonist (nifedipine) in acute pulmonary edema. American Journal of Medicine 66: 825–830, 1979
Rafflenbeul W, Lichtlen PR. Zum koncept der ‘dynamischen’ koronarstenose. Zeitschrift für Kardiologie 71: 439–444, 1982
Reddy PS, Uretsky BF, Steinfeld M. The hemodynamic effects of intravenous verapamil in patients on chronic propranolol therapy. American Heart Journal 107: 97–101, 1984
Robinson BF, Collier JG, Dobbs RJ. Comparative dilator effect of verapamil and sodium nitroprusside in forearm arterial bed and dorsal hand veins in man: functional differences between vascular smooth muscle in arterioles and veins. Cardiovascular Research 13: 16–21, 1979
Robinson BF, Dobbs RJ, Kelsey CR. Effects of nifedipine on resistance vessels, arteries and veins in man. British Journal of Clinical Pharmacology 10: 433–438, 1980
Robson RH, Vishwanath MC. Nifedipine and beta-blockade as a cause of cardiac failure. British Medical Journal 284: 104, 1982
Rosenthal SJ, Baim DS, Lamb IH, Schroeder JS. Effects of diltiazem hydrochloride capsules on cardiac hemodynamics and electrocardiographic function. Current Therapeutic Research 28: 319–325, 1980a
Rosenthal SJ, Ginsburg R, Lamb RH, Baim DS, Schroeder JS. Efficacy of diltiazem for control of symptoms of coronary arterial spasm. American Journal of Cardiology 46: 1027–1032, 1980b
Rouleau JL, Chatterjee K, Ports TA, Doyle MB, Hiramatju B, et al. Mechanism of relief of pacing-induced angina with oral verapamil: reduced oxygen demand. Circulation 67: 94–100, 1983
Rousseau MF, Veriter C, Detry JR, Brasseur L, Pouleur H. Impaired early left ventricular relaxation in coronary artery disease: effects of intracoronary nifedipine. Circulation 62: 764–772, 1980
Rowland E, Razis P, Sugrue D, Krikler DM. Acute and chronic haemodynamic and electrophysiological effects of nifedipine in patients receiving atenolol. British Heart Journal 50: 383–389, 1983
Sadick N, Roubin GS, Harris PJ, Hiroe M, Meares S, et al. Effect of intravenous verapamil on the haemodynamic response to exercise in patients with angina pectoris. In Persson et al. (Eds) A different approach in cardiovascular therapy calcium antagonism, pp. 91–98, 1982
Schanzenbächer P, Liebau G, Deeg P, Kochsiek K. Effect of intravenous and intracoronary nifedipine on coronary blood flow and myocardial oxygen consumption. American Journal of Cardiology 51: 712–717, 1983
Schick EC, Liang C, Heupler FA, Kahl FR, Kent KM, et al. Randomized withdrawal from nifedipine: placebo-controlled study in patients with coronary artery spasm. American Heart Journal 104: 690–697, 1982
Schmutzler H, Dorow P, Krais T, Rutsch W. Central haemodynamics under conditions of rest and load in patients with coronary artery disease treated with a combination of a beta-blocker and nifedipine. In Puech & Krebs (Eds) Fourth International Adalat Symposium, pp. 176–183, Excerpta Medica, Amsterdam-Oxford-Princeton, 1980
Seabra-Gomes R, Rickards A, Sutton R. Haemodynamic effects of verapamil and practolol in man. European Journal of Cardiology 4: 79, 1976
Serruys PW, Booman F, Steward R, Michels R, Reiber JHC, et al. Unstable angina pectoris and coronary arterial vasomotion: which role for nifedipine? In Rafflenbeul et al. (Eds) Unstable angina pectoris, pp. 103–120, George Thieme Verlag, Stuttgart-New York, 1981a
Serruys PW, Brower RW, ten Katen HJ, Bom AH, Hugenholtz PG. Regional wall motion from radiopaque markers after intravenous and intracoronary injection of nifedipine. Circulation 63: 584–591, 1981b
Serruys PW, de Jong JW, Harmsen E, Verdouw PD, Hugenholtz PG. Effect of intracoronary nifedipine on high-energy phosphate metabolism during repeated pacing-induced experimental ischemia. In Kaltenbach & Neufeld (Eds) Proceedings of the 5th International Adalat Symposium, pp. 340–353, Excerpta Medica, Amsterdam-Oxford-Princeton, 1982
Serruys PW, Hooghoudt TEH, Reiber JHC, Slager C, Brower RW, Hugenholtz PG. Influence of intracoronary nifedipine on left ventricular function, coronary vasomotility, and myocardial oxygen consumption. British Heart Journal 49: 427–431, 1983a
Serruys PW, Steward R, Booman F, Michels R, Reiber JHC, Hugenholtz PG. Can unstable angina pectoris be due to increased coronary vasomotor tone? European Heart Journal 1(Suppl. B): 71–85, 1980a
Serruys PW, Suryapranata H, Planellas J, Wijns W, Vanhaleweyk G, et al. Effects of short-term intravenous administration of diltiazem in left ventricular function and coronary haemodynamics in patients with coronary artery disease. Journal of Cardiovascular Pharmacology, 7: 1138–1148, 1985
Serruys PW, Van den Brand M, Brower RW, Hugenholtz PG. Regional cardioplegia and cardioprotection during transluminal angioplasty, which role for nifedipine. European Heart Journal 4(Suppl. C): 115–121, 1983b
Serruys PW, Van den Brand M, Ten Katen HJ, Brower RW. Regional wall motion following intra-bypass injection of nifedipine: design of a protocol and initial experience. In Fleckenstein & Roskamm (Eds) Calcium antagonists, pp. 282–292, Springer Verlag, Berlin-Heidelberg-New York, 1980b
Silke B, Verma SP, Nelson GIC, Ahuja RC, Hussain M, et al. The effects on left ventricular performance of nifedipine and verapamil in exercise induced angina pectoris. British Journal of Clinical Pharmacology 17: 735–743, 1984
Singh BN, Collett JT, Chew CYC. New perspectives in the pharmacologic therapy of cardiac arrhythmias. Progress in Cardiovascular Diseases 22: 243–301, 1980
Simonsen S, Nitter-Hauge S. Effect of nifedipine on coronary haemodynamics in patients with coronary arteriosclerotic disease. Acta Medica Scandinavica 204: 179–184, 1978
Specchia G, de Servi S, Falcone C, Angoli L, Gavazzi A, et al. Effects of nifedipine on coronary hemodynamic findings during exercise in patients with stable exertional angina. Circulation 68: 1035–1043, 1983
Staffurth JS, Emery P. Adverse interaction between nifedipine and beta-blockade. British Medical Journal 282: 225, 1981
Stone DL, Stephens ID, Banim SO. Coronary haemodynamic effects of nifedipine: comparison with glyceryl trinitrate. British Heart Journal 49: 442–446, 1983
Strauss WE, Parisi AF. Superiority of combined diltiazem and propranolol therapy for angina pectoris. Circulation 71: 951–957, 1985
Taburet AM, Singlas E, Colin JN, Banzet O, Thibonnier M, et al. Pharmacokinetic studies of nifedipine tablets. Correlation with antihypertensive effects. Hypertension 5(Suppl. 2): 29–33, 1983
Taeymans Y, Clozel JP, Caille G, Brevers G, Theroux P. Relationship between diltiazem plasma levels and its hemodynamic effects. Abstract. Circulation 66(Suppl. 2): 11–81, 1982
Tan ATH, Sadick N, Kelly DT, Harris PJ, Freedman SB, et al. Verapamil in stable effort angina: effects on left ventricular function evaluated with exercise radionuclide ventriculography. American Journal of Cardiology 49: 425–430, 1982
Theroux P, Waters DD, Debaisieux JC, Szlachcic J, Mizgala HF, et al. Hemodynamic effects of calcium antagonists after acute myocardial infarction. Clinical and Investigative Medicine 3: 81–85, 1980
Van den Brand M, Remme WJ, Meester GT, Tiggelaar-de Widt, De Ruiter R, et al. Hemodynamic effect of nifedipine in patients catheterized for coronary artery disease. In Lochner et al. (Eds) Proceedings of the 2nd International Adalat Symposium, pp. 145–153, Springer Verlag, Berlin-Heidelberg-New York, 1975
Vincenzi M, Allegri P, Gabaldo S, Maiolino P, Ometto R. Hemodynamic effects caused by IV administration of verapamil in healthy subjects. Arzneimittel-Forschung 26: 1221–1223, 1976
Vlietstra RE, Farias MAC, Frye RL, Smith HC, Ritman EL. Effect of verapamil on left ventricular function: a randomized, placebo-controlled study. American Journal of Cardiology 51: 1213–1217, 1983
Waters DD, Theroux P, Szlachaic J, Dauwe F. Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina. American Journal of Cardiology 48: 123–130, 1981
Winniford MD, Markham RV, Firth BG, Nicod P, Hillis LD. Hemodynamic and electrophysiologic effects of verapamil and nifedipine in patients on propranolol. American Journal of Cardiology 50: 704–710, 1982
Wolfe CL, Tilton GD, Hillis LD, Ashram NE, Winniford MD. Acute hemodynamic and electrophysiologic effects of propranolol in patients receiving diltiazem. American Journal of Cardiology 56: 47–50, 1985
Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, et al. Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs. Japanese Circulation Journal 42: 1–10, 1978
Yasue H, Omote S, Takizawa A, Nagao M, Miwa K, et al. Exertional angina pectoris caused by coronary arterial spasm: effects of various drugs. American Journal of Cardiology 43: 647–652, 1979
Zacca NM, Verani MS, Chahine RA, Miller RR. Effect of nifedipine on exercise-induced left ventricular dysfunction and myocardial hypoperfusion in stable angina. American Journal of Cardiology 50: 689–695, 1982
Zygelman M, Merillon JP, Guiomard A, Eustigneff F, Zannier D, et al. Effects hemodynamiques et coronariens du verapamil intraveineux dans l’insuffisance coronaire. Archives des Maladies du Coeur 74: 685–694, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soward, A.L., Vanhaleweyk, G.L.J. & Serruys, P.W. The Haemodynamic Effects of Nifedipine, Verapamil and Diltiazem in Patients with Coronary Artery Disease. Drugs 32, 66–101 (1986). https://doi.org/10.2165/00003495-198632010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198632010-00004